Camus attained a big milestone with starting manufacturing of formulations in year 2006. The focus area has majorly shifted to develop and manufacture products which involve complex technologies. By sales volume, Camus crossed USD 22 million in year 2014. We are heavily investing in development of innovative products. With four highly sophisticated manufacturing sites in India, having full scale Formulation Development centres, we have successfully created a basket of very unique and innovative products, which shall bring good returns to the company.
We have currently listed 4 formulations in Russia / CIS and 17 are under registration in various countries including Russia / CIS. All these products are technically very complex and unique, as “me too” generics are nowhere in business strategy of Camus.
Also, we have successfully registered more than 45 APIs in Russia / CIS and another 18 are under registration. Key focus areas are Tuberculosis, ARV, antibiotics and Oncology.
We are fortunate to work with the best names in the industry – like Mylan, Lupin, Glenmark, Biocon, Reliance Life, Sun Pharma, Acebright, Desano, Hisun etc to name a few.